Stem-cell therapy for diabetes cure: how close are we?

Area of Science:

• Regenerative Medicine
• Endocrinology
• Stem Cell Biology

Background:

• Type 1 diabetes treatment relies on insulin-producing cells, but donor cell scarcity is a major limitation.
• Stem cells offer a potential alternative source for generating insulin-producing cells.
• Current methods struggle with efficient and directed differentiation of stem cells into pancreatic endocrine lineages.

Purpose of the Study:

• To review sources of pancreatic islet stem cells from human tissues.
• To assess progress in pancreatic islet progenitor cell differentiation over the past two decades.
• To evaluate the clinical translatability of stem cell-based diabetes therapies.

Main Methods:

• Review of scientific literature on pancreatic islet stem cells.
• Analysis of studies on in vitro expansion and differentiation of progenitor/stem cells.
• Discussion of various human tissue sources for islet stem cells (embryonic, fetal, adult).

Main Results:

• Identification of various pancreatic islet stem cell populations from human embryonic, fetal, and adult tissues.
• Demonstration of in vitro expansion capabilities of progenitor/stem cell populations.
• Highlighting persistent difficulties in achieving efficient and directed differentiation towards endocrine pancreatic lineages.

Conclusions:

• Stem cells represent a promising, albeit challenging, avenue for addressing donor cell limitations in diabetes therapy.
• Significant progress has been made in understanding and expanding islet progenitor cells.
• Further research is needed to overcome differentiation hurdles for successful clinical translation.